Home » Vialis AG and iFactory to Deliver Real-Time Scheduling to Labs
Vialis AG and iFactory to Deliver Real-Time Scheduling to Labs
Vialis AG
PharmaManufacturing.com
12/19/2012
Vialis AG has announced a strategic partnership with iFactory Inc. to deliver real-time scheduling ability to the life sciences laboratory environment. iFactory’s real-time scheduling complements Vialis’ expertise in life sciences process optimization and further strengthens their paperless lab concept integrating modular solutions in a single workflow.
iFactory has adapted its patented manufacturing scheduling algorithm to offer intelligent, real-time scheduling to the laboratory environment delivering increased instrument load, resource productivity and on-time release. iLAB’s ground-breaking functionality is possible because it is not tied to a set of predefined rules; instead it analytically explores a large solution space, compares possible schedules and automatically selects the best schedule based on the optimization criteria.
iLAB’s innovative technology empower managers with better control of lab operations and the ability to realize previously unattainable productivity. The scheduler enables lab managers to proactively explore “what-if” scenarios to assist in strategic decision making and resource planning. iLAB is also able to generate and send up-to-date duty roster to workstations, tablets and handhelds.
“We are excited to partner with Vialis adding real-time scheduling to their Paperless Lab Solutions portfolio. There is a real need for automated scheduling in laboratories due to stricter regulations, increased workloads, and increasingly complex processes. Our solution represents the next generation of scheduling. It considers all complexities and constraints of laboratory operations and delivers optimized schedules which increase productivity and efficiency using existing resources”, stated iFactory’s CEO, Rainer Thierauf.
“We see a tremendous need for real-time scheduling in the lab domain at most of our customers. iFactory’s technological capabilities adapted to the lab domain ideally complement the process optimization initiatives that we support at so many customers by improving resource utilization and shortening cycle times. iFactory’s patented scheduling engine is the optimal extension to any Paperless Lab environment guaranteeing higher operational efficiency and continuous improvement”, commented Dr. Ulf Fuchslueger, CEO, Vialis AG.
More News:
-
06/18/2013
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
-
06/18/2013
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
-
06/18/2013
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
-
06/18/2013
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
-
06/17/2013
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
-
06/14/2013
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
-
06/14/2013
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
-
06/13/2013
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
-
06/13/2013
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
-
06/13/2013
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »
Get Connected Now!
- Featured White Papers

Print page